Endologix Inc. Reports 25% And 21% Revenue Growth For The Full Year And Fourth Quarter 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

IRVINE, Calif., Feb. 27, 2014 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2013.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC